Department News

New stem cell research led by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology, has identified novel therapeutic targets for the treatment of multiple sclerosis (MS) and other inflammatory diseases.

Nonprescription use of Ritalin may cause irreversible structural changes in certain areas of the brain, according to researchers in the Department of Pharmacology and Toxicology and UB’s Clinical and Research Institute on Addictions (CRIA).

Jennifer A. Martin, a doctoral student in the Department of Pharmacology and Toxicology, has received a prestigious Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience Award from the National Institutes of Health (NIH).

The National Institutes of Health is funding researchers in the Department of Pharmacology and Toxicology to study the effects of drinking, smoking and marijuana use during pregnancy.

Eleven faculty, three emeritus faculty and one staff member from the Jacobs School of Medicine and Biomedical Sciences were among those honored for notable achievement and service at the 15th annual University at Buffalo Celebration of Faculty and Staff Academic Excellence.

A preclinical study conducted by researchers in the Department of Pharmacology and Toxicology has shown for the first time that a class of proteins are important in the neurobiology of relapse or drug-seeking behaviors.

David Dietz, PhD, associate professor, has been appointed chair of the Department of Pharmacology and Toxicology.

Seventy-five student-scientists presented projects during the Eighth Annual Buffalo Summer Research Conference, an interdisciplinary forum marking the culmination of their summer research in Buffalo.

New research led by Panayotis (Peter) K. Thanos, PhD, a senior research scientist specializing in behavioral neuropharmacology at UB’s Research Institute on Addictions and the Department of Pharmacology and Toxicology, shows that exercise can help prevent relapse into cocaine addiction.

Research led by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology, has identified a new drug target for remyelination in multiple sclerosis (MS).